Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Corrie, P.G.; Marshall, A.; Nathan, P.D.; Lorigan, P.; Gore, M.; Tahir, S.; Faust, G.; Kelly, C.G.; Marples, M.; Danson, S.J.; Marshall, E.; Houston, S.J.; Board, R.E.; Waterston, A.M.; Nobes, J.P.; Harries, M.; Kumar, S.; Goodman, A.; Dalgleish, A.; Martin-Clavijo, A.; Westwell, S.; Casasola, R.; Chao, D.; Maraveyas, A.; Patel, P.M.; Ottensmeier, C.H.; Farrugia, D.; Humphreys, A.; Eccles, B.; Young, G.; Barker, E.O.; Harman, C.; Weiss, M.; Myers, K.A.; Chhabra, A.; Rodwell, S.H.; Dunn, J.A.; Middleton, M.R.; Investigators, AVAST-M; Nathan, Paul; Lorigan, Paul; Dziewulski, Peter; Holikova, Sonja; Panwar, Udaiveer; Tahir, Saad; Faust, Guy; Thomas, Anne; Corrie, Pippa; Sirohi, Bhawna; Kelly, Charles; Middleton, Mark; Marples, Maria; Danson, Sarah; Lester, James; Marshall, Ernest; Ajaz, Mazhar; Houston, Stephen; Board, Ruth; Eaton, David; Waterston, Ashita; Nobes, Jenny; Loo, Suat; Gray, Gill; Stubbings, Helen; Gore, Martin; Harries, Mark; Kumar, Satish; Goodman, Andrew; Dalgleish, Angus; Martin-Clavijo, Agustin; Marsden, Jerry; Westwell, Sarah; Casasola, Richard; Chao, David; Maraveyas, Anthony; Marshall, Ernest; Patel, Poulam; Ottensmeier, Christian; Farrugia, David; Humphreys, Alison; Eccles, Bryony; Dega, Renata; Herbert, Chris; Price, Christopher; Brunt, Murray; Scott-Brown, Martin; Hamilton, Joanna; Larry Hayward, Richard; Smyth, John; Woodings, Pamela; Nayak, Neena; Burrows, Lorna; Wolstenholme, Virginia; Wagstaff, John; Nicolson, Marianne; Wilson, Andrew; Barlow, Clare; Scrase, Christopher; Podd, Timothy; Gonzalez, Michael; Stewart, John; Highley, Martin; Wolstenholme, Virginia; Grumett, Simon; Goodman, Andrew; Talbot, Toby; Nathan, Kannon; Coltart, Robert; Gee, Bruce; Gore, Martin; Farrugia, David; Martin-Clavijo, Agustin; Marsden, Jerry; Price, Christopher; Farrugia, David; Nathan, Kannon; Coltart, Robert; Nathan, Kannon; Coltart, Robert

doi:10.1093/annonc/mdy229

All Outputs (1)

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2018)
Journal Article
Corrie, P., Marshall, A., Nathan, P., Lorigan, P., Gore, M., Tahir, S., …Coltart, R. (2018). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of oncology, 29(8), 1843 -1852. https://doi.org/10.1093/annonc/mdy229

Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recur... Read More about Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.